MRI-guided transurethral ultrasound ablation associated with less blood loss, shorter stays, and less pain than robotic prostatectomy.

A meta-analysis of nearly 25,000 patients undergoing radical prostatectomy supports adding presurgery MRI findings to ...

Francis Medical, Inc., a privately held medical device company based in Maple Grove, Minn., today announced that Aaron ...

PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...

Following the PRECISION trial, prostate multiparametric MRI has been adopted as the first-line investigation for suspected ...

Cribriform-positive prostate cancer outcomes needs to be further risk stratified to identify patients at high risk for metastasis.

Pre-treatment prostate MRI predicts recurrence and survival after surgery. Discover how imaging improves risk assessment.

HNL Lab Medicine and Ibex Medical Analytics announced a collaboration on AI-powered solutions for prostate cancer.

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...

First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...

While the risk of cancer increases as we get older, research shows the disease is also increasing among younger adults.